Idiopathic Hypersomnia Clinical Trial
Official title:
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia
The purpose of this study is to evaluate the safety and tolerability of administering a single intravenous (IV) infusion dose of TAK-925 to adult participants with idiopathic hypersomnia (IH).
The drug being tested in this study in participants with IH is called TAK-925. The study will have 2-treatment crossover groups. The study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of a single intravenous (IV) dose of Dose A in participants with IH. The study will enroll 40 patients. Participants will be randomly assigned to one of the two treatment sequence groups as indicated below: - TAK-925 + Placebo - Placebo + TAK-925 On Day 1 of each treatment period, TAK-925 or placebo will be administered as a single 9-hour IV infusion. The multicenter study will be conducted in the United States and Japan. The overall duration of treatment in this study is approximately 41 days including screening up to 28 days, confinement for 6 days and end of study follow up telephone call on Study Day 11. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04026958 -
Clarithromycin Mechanisms in Hypersomnia Syndromes
|
Phase 2 | |
| Completed |
NCT02512588 -
A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
|
Phase 2 | |
| Completed |
NCT01183312 -
Flumazenil for the Treatment of Primary Hypersomnia
|
Phase 1/Phase 2 | |
| Completed |
NCT03597555 -
Sodium Oxybate in Idiopathic Hypersomnia
|
Phase 2/Phase 3 | |
| Completed |
NCT03356938 -
The Role of the Circadian System in Neurological Sleep-wake Disorders
|
N/A | |
| Completed |
NCT03533114 -
A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
|
Phase 3 | |
| Active, not recruiting |
NCT03542851 -
A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia
|
Phase 2 | |
| Completed |
NCT05156047 -
A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
|
Phase 3 | |
| Enrolling by invitation |
NCT05371483 -
Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
|
||
| Not yet recruiting |
NCT06252571 -
a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial
|
Phase 2 | |
| Completed |
NCT04827329 -
Anesthetic Management of Patients With Chronic Sleep Disorders
|
||
| Not yet recruiting |
NCT06457945 -
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
|
N/A | |
| Recruiting |
NCT05875974 -
Ph4 PSG Combined JZP258-407
|
Phase 4 | |
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Completed |
NCT01146600 -
Clarithromycin for the Treatment of Hypersomnia
|
Phase 2 | |
| Recruiting |
NCT04330963 -
International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
|
||
| Recruiting |
NCT05615584 -
Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence
|
N/A | |
| Recruiting |
NCT05837091 -
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
|
Phase 4 | |
| Recruiting |
NCT05321355 -
Mainz Register of Patients With Sleep Disorders
|
||
| Active, not recruiting |
NCT05668754 -
Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH
|
Phase 2 |